Meeting
2022 ASCO Genitourinary Cancers Symposium
Safety lead-in of phase II SBRT and durvalumab with or without tremelimumab for unresectable and cisplatin-ineligible, locally advanced or metastatic bladder cancer.
Authors
Palak Kundu
Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA
Palak Kundu , Alan Lee , Alexandra Drakaki , Sandy Liu , John Shen , Arnold I. Chin , Karim Chamie , Albert Chang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03601455
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 517)
DOI
10.1200/JCO.2022.40.6_suppl.517
Abstract #
517
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Durvalumab and tremelimumab plus local tumor ablation (RFA or stereotactic radiotherapy) in patients with metastatic colorectal cancer with unresectable liver metastases: Results of the EORTC-1560-GITCG (ILOC) phase II study.
First Author: Jenny F. Seligmann
Poster
2016 ASCO Annual Meeting
A phase 3 study of first-line durvalumab (MEDI4736) ± tremelimumab versus standard of care (SoC) chemotherapy (CT) in patients (pts) with unresectable Stage IV urothelial bladder cancer (UBC): DANUBE.
First Author: Thomas Powles
Poster
2023 ASCO Annual Meeting
Phase I/II trial of durvalumab plus tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma: Final results.
First Author: Houda Bahig
Poster
2019 ASCO Annual Meeting
DUTRENEO Trial: A phase II randomized trial of DUrvalumab and TREmelimumab as NEOadjuvant approach in muscle-invasive urothelial bladder cancer (MIBC) patients prospectively selected by immune signature scores.
First Author: Enrique Grande